Reports Q4 revenue $121,000 vs $209,000 last year. "Longeveron had a productive 2022, executing on multiple key milestones as we continued to advance Lomecel-BTM for multiple indications," said Wa’el Hashad, Chief Executive Officer. "Earlier this year, the full data from our ELPIS I trial of Lomecel-BTM for infants with HLHS was published in European Heart Journal Open. We are excited to continue advancing this opportunity through our ongoing Phase 2 ELPIS II trial. We have also made progress with our Japan Aging-Related Phase 2 study. We look forward to building on this progress through the rest of 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LGVN:
- Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
- Longeveron Appoints Wa’el Hashad as Chief Executive Officer
- Longeveron appoints Wa’el Hashad as Chief Executive Officer
- Longeveron announces publication of final data from ELPIS I trial
